The pharmacokinetics and pharmacodynamics of lisuride in healthy volunteers after intravenous, intramuscular, and subcutaneous injection
- PMID: 2050175
- DOI: 10.1007/BF00265851
The pharmacokinetics and pharmacodynamics of lisuride in healthy volunteers after intravenous, intramuscular, and subcutaneous injection
Abstract
The plasma concentration of lisuride and prolactin have been measured in twelve healthy male volunteers after IV, IM or SC injection of 25 micrograms lisuride hydrogen maleate as an aqueous solution. After IV administration the plasma lisuride fell in two phases with half-lives of 14 min and 1.5 h. Total clearance was 13 ml.min-1.kg-1. After IM and SC injection the plasma concentrations peaked at 12 to 15 min and the profiles were similar to that found after IV administration. The systemic availabilities were 90% and 94%, respectively. Prolactin concentrations were reduced by a maximum of 60% relative to the normal circadian rhythm after all three routes of administration. The treatments were well tolerated, the only adverse reactions reported by some of the volunteers being mild, transient dizziness, tiredness, and nausea.
Similar articles
-
Radioimmunoassay of plasma lisuride in man following intravenous and oral administration of lisuride hydrogen maleate: effect on plasma prolactin level.Eur J Clin Pharmacol. 1981;20(1):47-51. doi: 10.1007/BF00554666. Eur J Clin Pharmacol. 1981. PMID: 7308272
-
Pharmacokinetics of lisuride after subcutaneous infusion.J Neural Transm Suppl. 1988;27:71-4. doi: 10.1007/978-3-7091-8954-2_8. J Neural Transm Suppl. 1988. PMID: 3165439
-
Pharmacokinetics and pharmacodynamics of terguride following intramuscular administration in cows and goats.Acta Physiol Pol. 1989 Jan-Feb;40(1):139-44. Acta Physiol Pol. 1989. PMID: 2603744
-
Pharmacokinetics and pharmacodynamics in man of the dopamine antagonist ergot derivative, bromerguride.Eur J Clin Pharmacol. 1986;31(2):165-8. doi: 10.1007/BF00606653. Eur J Clin Pharmacol. 1986. PMID: 3803415
-
A review of paediatric injectable drug delivery to inform the study of product acceptability - An introduction.Eur J Pharm Biopharm. 2023 Jul;188:265-270. doi: 10.1016/j.ejpb.2023.04.010. Epub 2023 Apr 24. Eur J Pharm Biopharm. 2023. PMID: 37100092 Review.
Cited by
-
A Combined In Vitro/In Silico Approach to Identifying Off-Target Receptor Toxicity.iScience. 2018 Jun 29;4:84-96. doi: 10.1016/j.isci.2018.05.012. Epub 2018 May 18. iScience. 2018. PMID: 30240756 Free PMC article.
-
Dopaminergic regulation of inflammation and immunity in Parkinson's disease: friend or foe?Clin Transl Immunology. 2023 Sep 29;12(10):e1469. doi: 10.1002/cti2.1469. eCollection 2023. Clin Transl Immunology. 2023. PMID: 37781343 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous